8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) February 7, 2018

SONOMA PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Delaware	001-33216	68-0423298
(State or other jurisdiction	(Commission	(IRS Employer
of incorporation)	File Number)	Identification No.)

1129 N. McDowell Blvd.

Petaluma, CA 94954

(Address of principal executive offices)

(Zip Code)

(707) 283-0550

(Registrant’s telephone number, including area code)

Not applicable.

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 2.02        Results of Operations and Financial Condition.

On February 7, 2018, Sonoma Pharmaceuticals, Inc. issued a press release announcing financial results for its fiscal quarter ended December 31, 2017. The full text of the press release is furnished as Exhibit 99.1. The information furnished therein shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that Section.

This report contains forward-looking statements. Forward-looking statements include, but are not limited to, statements that express the Company’s intentions, beliefs, expectations, strategies, predictions or any other statements related to its future activities or future events or conditions. These statements are based on current expectations, estimates and projections about the Company’s business based, in part, on assumptions made by management. These statements are not guarantees of future performances and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors, including those risks discussed in the Company’s Annual Report on Form 10-K and in other documents that it files from time to time with the SEC. Any forward-looking statements speak only as of the date on which they are made, and the Company does not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of this report, except as required by law.

Item 9.01        Financial Statements and Exhibits.

99.1	Press Release issued by Sonoma Pharmaceuticals, Inc., dated February 7, 2018.
99.2	Presentation used by Sonoma Pharmaceuticals, Inc. on February 7, 2018.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Sonoma Pharmaceuticals, Inc.
	(Registrant)
Date: February 7, 2018	/s/ Robert Miller
	Name: Robert Miller
	Title: Chief Financial Officer

EX-99.1

Exhibit 99.1

 

FOR IMMEDIATE RELEASE

Sonoma Pharmaceuticals Reports Record Total Revenue of $4.8 million for Third Quarter FY 2018 with

Year over Year Product Revenue Growth of 46%

· Product revenue up 12% compared to September 2017 quarter

· U.S. product revenue up 27% compared to the September 2017 quarter

· Cash on hand equals $8.6 million at quarter end

Conference Call Begins at 4:30pm EST Today

Slide Presentation to Review in Tandem with Earnings Call Available at http://ir.sonomapharma.com/events.cfm

PETALUMA, Calif.—(February 7, 2018)—Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA, warrants SNOAW), a specialty pharmaceutical company that develops and markets unique and effective solutions for the treatment of dermatological conditions and advanced tissue care, today announced financial results for the third quarter of fiscal year 2018, ended December 31, 2017.

Total revenue was $4.8 million for the third quarter as compared to $3.4 million for the same period last year. Product revenues of $4.6 million were up 46%, or $1.5 million, when compared to the same period last year, as result of strong growth in the United States, Europe, and Latin America.

“This quarter’s revenue of $4.8 million is our highest quarterly revenue in the history of the company. This record revenue has been driven by robust year-over-year and quarter-over-quarter growth in the prescription dermatology business – our primary focus over the last three years. These results include sales growth in our Levicyn, Celacyn, Ceramax, SebuDerm and Mondoxyne products,” said Jim Schutz, Sonoma Pharmceuticals CEO.

Business Highlights

· Robust portfolio of six non-steroidal products for treatment of atopic and seborrheic dermatitis, surgical procedures, severe acne, skin repair, descaling, and scar management.

· Company has 30 sales representatives and five sales managers, focused exclusively on the dermatology prescription market.

· Received approval by Brazilian Ministério da Saúde for seven non-steroidal and non-antibiotic, topical dermatology products in October 2017.

· Received approval from United Arab Emirates (UAE) Ministry of Health & Prevention of three products for daily eyelid hygiene, antimicrobial nasal cleaning and antiseptic mouth and throat rinse.

· Received two FDA clearances to add antimicrobial language to both AlevicynSG™ Spray Gel and Alevicyn™ Dermal Spray solution.

Results for the Three months Ended December 31, 2017

Product revenues in the United States, of $2.9 million, for the three months ended December 31, 2017, increased by $1.2 million, or 73%, as compared to $1.7 million for the three months ended December 31, 2016. This increase was mostly the result of higher sales of the company’s dermatology, acute care and animal health care products.

Product revenue in Latin America for the quarter ended December 31, 2017, was $772,000. This amount reflects the sale of products to Invekra, following the completion of Sonoma’s asset sale to Invekra in October 2016. Sonoma will continue to supply products to Invekra until its manufacturing facility is operational.

Product revenue in Europe and the rest of the world of $992,000, for the three months ended December 31, 2017, decreased by $46,000, or 4%, as compared to $1.0 million for the three months ended December 31, 2016. This decrease was the result of lower sales in China and the Middle East, mostly offset by higher sales in Europe, Singapore, Hong Kong and India.

1

Sonoma reported gross profit of $2.4 million, or 49% of total revenue, during the three months ended December 31, 2017, compared to a gross profit of $1.7 million, or 51% of total revenue in the same period in the prior year. The decrease in gross profit, as a percentage of revenue, was primarily due to the lower profitability in Latin America related to the higher sales to Invekra at a very low profit, partly offset by higher margins in the United States caused by the strong growth of the more profitable dermatology product lines.

Operating expenses minus non-cash expenses during the third quarter of fiscal year 2018 were $4.9 million, up $555,000, or 13%, as compared to the same period in the prior year. This increase in operating expenses was mostly due to higher sales, marketing and administrative expenses in the United States related to the growth of a direct sales force in dermatology, partly offset by a decline in Latin American expenses. A key driver to the growth in operating expenses is the increase in the number of sales representatives, compared to the same period last year.

Loss from operations was $3.2 million, down $365,000, compared to $3.6 million for the same period last year. Operating loss less non-cash expenses (EBITDA) for the three months ended December 31, 2017, was $2.4 million, compared to $2.5 million for the same period last year.

As of December 31, 2017, Sonoma had cash and cash equivalents of $8.6 million, as compared to $10 million as of September 30, 2017.

Results for the Nine Months Ended December 31, 2017

Total revenues of $13 million increased by $4.2 million, or 48%, for the nine months ended December 31, 2017, as compared to $8.8 million for the nine months ended December 31, 2016. Product revenue of $12.4 million for the nine months ended December 31, 2017, increased $4.2 million, or 52%, compared to the same period last year. This increase in product revenue was driven by strong growth in the United States, up $2.3 million, or 48% and by higher sales in Europe and rest of world, up $337,000, or 11%.

The company reported gross profit related to sales of its products of $6.0 million, or 46% of total revenues, for the nine months ended December 31, 2017.

Total operating expenses less non-cash expenses of $13.8 million increased $1.7 million, or 14%, for the nine months end December 31, 2017, as compared to the same period in the prior year. This increase was primarily due to higher costs of the direct sales force for dermatology. Operating loss less non-cash expenses (EBITDA) of $7.5 million, for the nine months ended December 31, 2017, was down $572,000, compared to $8.1 million for the same period last year.

Conference Call

Sonoma’s management will hold a conference call today to discuss third quarter fiscal year 2018 results and answer questions, beginning at 4:30 p.m. EST. Individuals interested in participating in the conference call may do so by dialing 877-303-7607 for domestic callers or 973-638-3203 for international callers. Those interested in listening to the conference call live via the Internet may do so at http://ir.sonomapharma.com/events.cfm. Please log on approximately 30 minutes prior to the presentation in order to register and download the appropriate software. Also, participants can download a graphical presentation of the quarterly results at this same site, which can provide greater granular detail in conjunction with the call.

A telephone replay will be available for seven days following the conclusion of the call by dialing 855-859-2056 for domestic callers, or 404-537-3406 for international callers, and entering conference code 5949729. A webcast replay will be available on the site at http://ir.sonomapharma.com/events.cfm for one year following the call.

Sale of Latin American Business and Impact on Accounting Treatment

With the sale of the Latin American business during the third quarter ended December 31, 2016, the components of the financial statements related to this transaction have been classified as a discontinued business for accounting purposes and in accordance with this accounting treatment, the income statement and balance sheet have been retroactively revised to reflect the revenue, expenses and balance sheet items of the continuing businesses for this fiscal year and last fiscal year. All of the income statement categories related to Latin America have been condensed to a one line item on the income statement as “Income from discontinued operations.” Also, the discontinued balance sheets items have been listed separately from the continuing operations. As a result, the comparison of results discussed in this press release relate primarily to the continuing businesses in accordance with generally accepted accounting principles.

About Sonoma Pharmaceuticals, Inc.

Sonoma is a specialty pharmaceutical company that develops and markets unique and effective solutions for the treatment of dermatological conditions and advanced tissue care. The company’s products, which are sold throughout the United States and internationally, have improved outcomes for more than five million patients globally by reducing infections, itch, pain, scarring and harmful inflammatory responses. The company's headquarters are in Petaluma, California, with manufacturing operations in the United States and Latin America. European marketing and sales are headquartered in Roermond, Netherlands. More information can be found at www.sonomapharma.com.

2

Forward-Looking Statements

Except for historical information herein, matters set forth in this press release are forward-looking within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial and technology progress and future financial performance of Sonoma Pharmaceuticals, Inc. and its subsidiaries (the “Company”). These forward-looking statements are identified by the use of words such as “believe,” “achieve,” and “strive,” among others. Forward-looking statements in this press release are subject to certain risks and uncertainties inherent in the Company’s business that could cause actual results to vary, including such risks that regulatory clinical and guideline developments may change, scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual patient settings, protection offered by the Company’s patents and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the Company’s products will not be as large as expected, the Company’s products will not be able to penetrate one or more targeted markets, revenues will not be sufficient to meet the Company’s cash needs, fund further development and clinical studies, as well as uncertainties relative to varying product formulations and a multitude of diverse regulatory and marketing requirements in different countries and municipalities, and other risks detailed from time to time in the Company’s filings with the Securities and Exchange Commission. The Company disclaims any obligation to update these forward-looking statements, except as required by law.

Sonoma Pharmaceuticals™, Alevicyn™, Celacyn™, SebuDerm™ and Microcyn® Technology are trademarks or registered trademarks of Sonoma Pharmaceuticals, Inc. All other trademarks and service marks are the property of their respective owners.

Media and Investor Contact:

Sonoma Pharmaceuticals, Inc.

Dan McFadden

VP of Public and Investor Relations

(425) 753-2105

dmcfadden@sonomapharma.com

3

SONOMA PHARMACEUTICALS, INC. AND SUBSIDIARIES

Condensed Consolidated Balance Sheets

(In thousands, except share and per share amounts)

	December 31,			March 31,
	2017			2017
	(Unaudited)
ASSETS
Current assets:
Cash and cash equivalents	$	8,625		$	17,461
Accounts receivable, net		2,609			2,108
Inventories, net		2,701			2,221
Prepaid expenses and other current assets		1,508			616
Current portion of deferred consideration, net of discount		229			237
Total current assets		15,672			22,643
Property and equipment, net		1,200			1,239
Deferred consideration, net of discount, less current portion		1,392			1,497
Other assets		91			80
Total assets	$	18,355		$	25,459
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$	1,400		$	1,255
Accrued expenses and other current liabilities		1,515			1,302
Deferred revenue		180			345
Deferred revenue Invekra		140			176
Current portion of long-term debt		12			123
Current portion of capital leases		146			74
Taxes payable		–			13
Total current liabilities		3,393			3,288
Long-term deferred revenue Invekra		492			527
Long-term debt, less current portion		35			45
Long-term capital leases, less current portion		179			168
Total liabilities		4,099			4,028
Commitments and Contingencies
Stockholders’ Equity
Convertible preferred stock, $0.0001 par value; 714,286 shares authorized, none issued and outstanding at December 31, 2017 and March 31, 2017, respectively		–			–
Common stock, $0.0001 par value; 12,000,000 shares authorized at December 31, 2017 and March 31, 2017, 4,637,541 and 4,289,322 shares issued and outstanding at December 31, 2017 and March 31, 2017, respectively		1			1
Additional paid-in capital		171,332			168,709
Accumulated deficit		(152,677	)		(143,101	)
Accumulated other comprehensive loss		(4,400	)		(4,178	)
Total stockholders’ equity		14,256			21,431
Total liabilities and stockholders’ equity	$	18,355		$	25,459

4

SONOMA PHARMACEUTICALS, INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Comprehensive (Loss) Income

(In thousands, except per share amounts)

(Unaudited)

	Three Months Ended December 31,						Nine Months Ended December 31,
	2017			2016			2017			2016
Revenues
Product	$	4,647		$	3,174		$	12,394		$	8,158
Service		196			187			609			638
Total revenues		4,843			3,361			13,003			8,796
Cost of revenues
Product		2,308			1,476			6,529			4,507
Service		167			179			496			568
Total cost of revenues		2,475			1,655			7,025			5,075
Gross profit		2,368			1,706			5,978			3,721
Operating expenses
Research and development		349			487			1,099			1,226
Selling, general and administrative		5,219			4,784			14,319			12,557
Total operating expenses		5,568			5,271			15,418			13,783
Loss from operations		(3,200	)		(3,565	)		(9,440	)		(10,062	)
Interest expense		(11	)		–			(31	)		(2	)
Interest income		14			6			85			8
Other income (expense), net		10			282			(179	)		276
Net loss from continuing operations before income taxes		(3,187	)		(3,277	)		(9,565	)		(9,780	)
Tax benefit		–			4,040			–			4,040
Net (loss) income from continuing operations		(3,187	)		763			(9,565	)		(5,740	)
Net income from discontinued operations (net of tax)		–			15,465			–			17,450
Net (loss) income	$	(3,187	)	$	16,228		$	(9,565	)	$	11,710
Net (loss) income per share: basic
Continuing operations	$	(0.73	)	$	0.18		$	(2.21	)	$	(1.36	)
Discontinued operations		–			3.66			–			4.15
	$	(0.73	)	$	3.84		$	(2.21	)	$	2.79
Weighted-average number of shares used in per share calculations: basic		4,392			4,225			4,333			4,209
Net (loss) income per share: diluted
Continuing operations	$	(0.73	)	$	0.18		$	(2.21	)	$	(1.36	)
Discontinued operations		–			3.66			–			4.15
	$	(0.73	)	$	3.84		$	(2.21	)	$	2.79
Weighted-average number of shares used in per share calculations: diluted		4,392			4,228			4,333			4,209
Other comprehensive (loss) income
Net (loss) income	$	(3,187	)	$	16,228		$	(9,565	)	$	11,710
Foreign currency translation adjustments		(377	)		(416	)		(222	)		(817	)
Comprehensive (loss) income	$	(3,564	)	$	15,812		$	(9,787	)	$	10,893

5

SONOMA PHARMACEUTICALS, INC. AND SUBSIDIARIES

Reconciliation of GAAP measures to non-GAAP measures

(In thousands) and (Unaudited)

	Three Months Ended December 31,						Nine Months Ended December 31,
	2017			2016			2017			2016
(1) Loss from operations minus non-cash expenses (EBITDA):
GAAP loss from operations as reported	$	(3,200	)	$	(3,565	)	$	(9,440	)	$	(10,062	)
Non-cash adjustments:
Stock-based compensation		692			1,013			1,592			1,830
Depreciation and amortization		125			60			366			178
Non-GAAP loss from operations minus non-cash expenses (EBITDA)	$	(2,383	)	$	(2,492	)	$	(7,482	)	$	(8,054	)
(2) Net loss minus non-cash expenses:
GAAP net income (loss) as reported	$	(3,187	)	$	16,228		$	(9,565	)	$	11,710
Non-cash adjustments:
Stock-based compensation		692			1,013			1,592			1,830
Depreciation and amortization		125			60			366			178
Non-GAAP net income (loss) minus non-cash expenses	$	(2,370	)	$	17,301		$	(7,607	)	$	13,718
(3) Operating expenses minus non-cash expenses
GAAP operating expenses as reported	$	5,568		$	5,271		$	15,418		$	13,783
Non-cash adjustments:
Stock-based compensation		(649	)		(950	)		(1,456	)		(1,633	)
Depreciation and amortization		(57	)		(14	)		(154	)		(30	)
Non-GAAP operating expenses minus non-cash expenses	$	4,862		$	4,307		$	13,808		$	12,120

(1) Loss from operations minus non-cash expenses (EBITDAS) is a non-GAAP financial measure. The Company defines operating loss minus non-cash expenses as GAAP reported operating loss minus operating depreciation and amortization, and operating stock-based compensation. The Company uses this measure for the purpose of modifying the operating loss to reflect direct cash related transactions during the measurement period.

(2) Net loss minus non-cash expenses is a non-GAAP financial measure. The Company defines net loss minus non-cash expenses as GAAP reported net loss minus depreciation and amortization, stock-based compensation, and non-cash foreign exchange transaction losses. The Company uses this measure for the purpose of modifying the net loss to reflect only those expenses to reflect direct cash transactions during the measurement period.

(3) Operating expenses minus non-cash expenses is a non-GAAP financial measure. The Company defines operating expenses minus non-cash expenses as GAAP reported operating expenses minus operating depreciation and amortization, and operating stock-based compensation. The Company uses this measure for the purpose of identifying total operating expenses involving cash transactions during the measurement period.

6

SONOMA PHARMACEUTICALS, INC. AND SUBSIDIARIES

Product related revenue schedules

(In thousands) and (Unaudited)

The following table shows the Company’s product revenues by geographic region:

	Three months ended December 31,
	2017		2016		$ Change			% Change
United States	$	2,883	$	1,671	$	1,212			73%
Latin America		772		465		307			66%
Europe and Rest of the World		992		1,038		(46	)		(4%	)
Total	$	4,647	$	3,174	$	1,473			46%

	Nine months ended December 31,
	2017		2016		$ Change		% Change
United States	$	7,010	$	4,741	$	2,269		48%
Latin America		2,095		465		1,630		351%
Europe and Rest of the World		3,289		2,952		337		11%
Total	$	12,394	$	8,158	$	4,236		52%

In connection with the Company’s sale of its Latin America business to Invekra, product related revenues were reclassified from continuing operations to discontinued operations. The amounts were classified in the prior periods as Latin America sales. The amounts reclassified are as follows:

	Three Months Ended December 31,
	2017		2016
Product revenues	$	–	$	359
Product license fees and royalties		–		262
Total product related revenues	$	–	$	621

	Nine Months Ended December 31,
	2017		2016
Product revenues	$	–	$	2,693
Product license fees and royalties		–		412
Total product related revenues	$	–	$	3,105

7

EX-99.2

Exhibit 99.2

NASDAQ: SNOA SONOMA PHARMACEUTICALS THIRD QUARTER FY2018 RESULTS February 7, 2018

NASDAQ: SNOA Page Agenda 2 Welcome / Introduction December 31, 2017 Highlights Financial Review Q+A Jim Schutz Jim Schutz Bob Miller

NASDAQ: SNOA Page Forward - Looking Statement Except for historical information herein, matters set forth in this presentation are forward - looking within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial and technology progress and future financial performance of Sonoma Pharmaceuticals, Inc. and its subsidiaries (the “Company”). These forward - looking statements are identified by the use of words such as “believe,” “achieve,” and “strive,” among others. Forward - looking statements in this press release are subject to certain risks and uncertainties inherent in the Company’s business that could cause actual results to vary, including such risks that regulatory clinical and guideline developments may change, scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual patient settings, protection offered by the Company’s patents and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the Company’s products will not be as large as expected, the Company’s products will not be able to penetrate one or more targeted markets, revenues will not be sufficient to fund further development and clinical studies, as well as uncertainties relative to varying product formulations and a multitude of diverse regulatory and marketing requirements in different countries and municipalities, and other risks detailed from time to time in the Company’s filings with the Securities and Exchange Commission. The Company disclaims any obligation to update these forward - looking statements, except as required by law. 3

NASDAQ: SNOA Page Results from the Quarter Ended December 2017 Total Net Revenues = $4,834,000 * • Product revenue up 46% versus same period last year • US Product revenue up 27% versus quarter ended 30 Sep 2017 4 US Dermatology Revenue = $2,207,000 * • Up 78% versus same period last year • Up 36% versus quarter ended 30 Sep 2017 EBITDA during the period = ($2,383,000) Cash = $8,625,000 * Highest in company history

NASDAQ: SNOA Page Fiscal YTD Milestones Jan - Three UAE approvals for blepharitis , chronic rhinosinusitis and oral care Nov + Dec - Three FDA approvals to expand indications to add antimicrobial language Oct - Seven Brazilian dermatology approvals Sep - Launched Loyon, indicated for scaling and erythema for various dermatoses Jun - Two Singapore dermatology approvals Apr - Hired 13 additional sales reps, totaling 30 reps and 5 managers Apr - Two UAE dermatology approvals Mar - FDA approval for Loyon Mar - Received final $1.5M of $19.5M payment from LatAm partner 5

NASDAQ: SNOA Page 6 Differentiated, Effective Solutions … for atopic dermatitis and eczema Ceramax ™ with Lipogrid ® Technology has been designed to control release and penetrate deep. Fluorescent microscopy shows the lipids in Lipogrid® Technology penetrate beyond the stratum corneum (SC) into the epidermis (E) 1 Ceramax™ contains selected lipids and a lipid precursor designed to easily penetrate the bilayers of the skin by blending with the natural lipid building blocks.

Dec 2017 QTR vs Dec 2016 QTR & Sept 2017 QTR 7 Quarter Ended Quarter Ended Dec 31 , 2016 Quarter Ended Sept 30, 2017 Dec 31, 2017 œ Amount Variance ¸ Amount Variance ¸ Total net revenues $4,843 $3,361 $1,482 44 ¸ $4,325 $518 12 ¸ Product revenues $4,647 $3,174 $1,473 46 ¸ $4,144 $503 12 ¸ U.S. revenues $2,883 $1,671 $1,212 73 ¸ $2,268 $615 27 ¸ U.S. dermatology net revenues $2,207 $1,237 $970 78 ¸ $1,621 $586 ®± ¸ U.S. dermatology gross revenue $4,647 $2,414 $2,233 ´®¸ $4,241 $406 ¬«¸ Operating expenses minus non - cash expenses $4,862 $4,307 $555 13 ¸ $4,237 $625 15 ¸ Net loss minus non - cash expenses (EBITDA) $2,383 $2,492 ($109) § 4 ¸ $2,263 $120 5 ¸ Cash & cash equivalents $8,625 $18,983 ($10,358) - 55% $9,983 ($1,358) § 14 ¸ * dollars in thousands, unaudited

NASDAQ: SNOA Page 8 Prescription Units Shipped for Dermatology Product Lines 0 1,106 2,724 3,361 4,059 3,769 4,190 6,201 6,827 7,175 5,712 6,757 7,327 7,863 0 39 1,043 2,305 3,103 2,833 3,382 4,298 4,405 4,204 3,488 4,914 4,938 4,930 0 134 582 222 318 414 921 1,217 1,733 1,699 0 689 1,410 1,908 1,440 1,080 1,212 2,382 0 24 648 930 948 1,206 0 1,008 24 0 1,145 3,767 5,666 7,162 6,736 8,154 11,410 12,960 13,725 12,209 14,898 17,166 18,104 0 2,000 4,000 6,000 8,000 10,000 12,000 14,000 16,000 18,000 20,000 Sep-14 QTR Ended Dec-14 QTR Ended Mar-15 QTR Ended Jun-15 QTR Ended Sep-15 QTR Ended Dec-15 QTR Ended Mar-16 QTR Ended Jun-16 QTR Ended Sep-16 QTR Ended Dec-16 QTR Ended Mar-17 QTR Ended Jun-17 QTR Ended Sep-17 QTR Ended Dec-17 QTR Ended Total Dispensed Prescriptions Alevicyn Celacyn Mondoxyne Ceramax Sebuderm Loyon Total Source: IMS Health NPA Average Quarter over Quarter Growth for Last 8 Quarters of 14% - December Quarter up 5% over September Quarter - September Quarter up 15% over June Quarter - June Quarter up 22% over March Quarter

NASDAQ: SNOA Total Q4 $2,552,720 + 7% Total Q3 $2,393,001 + 15% Total Q4 $2,791,258 + 17% Total Q2 $2,088,619 + 26% Total Q4 $2,791,258 + 17% 9 Average Quarter over Quarter Growth for Last 4/ 6 Quarters: • Total Prescription Units Sold Quarterly Growth of 19%/ 24% • Ceramax (skin repair) Quarterly Growth of 24%/41% • Mondoxyne (acne) Quarterly Growth of 45%/43% • Celacyn (scar) Quarterly Growth of 21%/ 18% • Alevicyn (dermatitis) Quarterly Growth of 14%/ 19% Total Q3 $4,542,947 + 9% Total Q3 $2,344,857 + 31% $631,328 $807,439 $1,072,466 $814,114 $1,174,078 $1,397,080 $1,626,721 $439,642 $499,821 $560,899 $475,097 $827,691 $936,113 $1,045,486 $120,024 $170,590 $231,840 $497,232 $660,662 $1,012,060 $795,746 $155,025 $317,183 $475,092 $362,426 $297,445 $335,966 $748,500 $0 $500,000 $1,000,000 $1,500,000 $2,000,000 $2,500,000 $3,000,000 $3,500,000 $4,000,000 $4,500,000 $5,000,000 Sep-14 QTR Ended Dec-14 QTR Ended Mar-15 QTR Ended Jun-15 QTR Ended Sep-15 QTR Ended Dec-15 QTR Ended Mar-16 QTR Ended Jun-16 QTR Ended Sep-16 QTR Ended Dec-16 QTR Ended Mar-17 QTR Ended Jun-17 QTR Ended Sep-17 QTR Ended Dec-17 QTR Ended TRX MBS DOLLARS Total Prescription Units Sold in Dollars at Sale Price For QTR 3/2016 through QTR 12/2017 Alevicyn Celacyn Mondoxyne Ceramax Sebuderm Loyon Source: IMS Health NPA Average Quarter over Quarter Growth for Last 4/ 6 Quarters: • Total Prescription Units Sold Quarterly Growth of 19%/ 24% • Ceramax (skin repair) Quarterly Growth of 24%/41% • Mondoxyne (acne) Quarterly Growth of 45%/43% • Celacyn (scar) Quarterly Growth of 21%/ 18% • Alevicyn (dermatitis) Quarterly Growth of 14%/ 19% Total Q1 $1.3 mm + 40% Total Q2 $1.8 mm + 33% Total Q3 $2.3 mm + 31% Total Q4 $2.3 mm - 3% Total Q1 $3.2 mm + 39% Total Q2 $4.2 mm + 32% Total Q3 $4.5 mm + 9%